IN THIS INVENTION, THERE ARE PROVIDED NOVEL ANTIBIOTICS, BISPOLIDE B1, BISPOLIDE B2A, BISPOLIDE B2B AND BISPOLIDE B3 WHICH ARE EACH A COMPOUND HAVING THE FORMULA (II): WHEREIN R¹ AND R² EACH DENOTE A HYDROGEN ATOM OR METHYL GROUP (-CH3), AND R¹ AND R² ARE EACH A HYDROGEN ATOM FOR BISPOLIDE B1 R¹ IS A HYDROGEN ATOM AND R² IS METHYL GROUP FOR BISPOLIDE B2A R¹ IS METHYL GROUP AND R² IS A HYDROGEN ATOM FOR BISPOLIDE B2B AND R¹ AND R² ARE EACH METHYL GROUP FOR BISPOLIDE B3. BISPOLIDE B1, BISPOLIDE B2A, BISPOLIDE B2B AND BISPOLIDE B3 MAY COLLECTIVELY BE NAMED AS A BISPOLIDE B AND ARE EACH AN ANTIBIOTIC HAVING A HIGH ANTIBACTERIAL ACTIVITY AGAINST BACTERIA SUCH AS GRAM-POSITIVE BACTERIA, INCLUDING METHICILLIN-RESISTANT STRAINS OF STAPHYLOCOCCUS AUREUS. IN THIS INVENTION, THERE IS ALSO PROVIDED A PROCESS OF PRODUCING A BISPOLIDE B COMPRISING CULTIVATING A MICROBIAL STRAIN DESIGNATED AS MICROBISPORA SP. A34030 (DEPOSITED UNDER AN ACCESS NUMBER OF FERM BP-10505). THERE IS FURTHER PROVIDED A PHARMACEUTICAL COMPOSITION COMPRISING A BISPOLIDE B AS AN ACTIVE INGREDIENT.